Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citation
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Items 101–200 of 429
Ziegler, R. J., Yew, N. S., Li, C., Cherry, M., Berthelette, P., Romanczuk, H., Ioannou, Y. A., Zeidner, K. M., Desnick, R. J., & Cheng, S. H. (1999) · Human Gene Therapy · doi:10.1089/10430349950017671 · Cited by 101
Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives
Rolling, F. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302366 · Cited by 100
Reding, M. T., Wu, H., Krampf, M. R., Okita, D. K., Diethelm-Okita, B. M., Christie, B. A., Key, N. S., & Conti‐Fine, B. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614081 · Cited by 100
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer
Wang, L., Cao, O., Swalm, B., Dobrzynski, E., Mingozzi, F., & Herzog, R. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302539 · Cited by 98
Chadeuf, G., Favre, D., Tessier, J., Provost, N., Nony, P., Kleinschmidt, J., Moullier, P., & Salvetti, A. (2000) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200007/08)2:4<260::aid-jgm111>3.0.co;2-8 · Cited by 87
Mandel, R. J., Snyder, R. O., & Leff, S. E. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7203 · Cited by 97
Self-citationGene therapy for the hemophilias
Kay, M. A., & High, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9973 · Cited by 96
Self-citationInnate Immune Recognition of Viruses and Viral Vectors
Huang, X., & Yang, Y. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.141 · Cited by 92
Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina
McGee Sanftner, L. H., Rendahl, K. G., Quiroz, D., Coyne, M., Ladner, M., Manning, W. C., & Flannery, J. G. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0308 · Cited by 94
Advances toward Gene Therapy for Hemophilia at the Millennium
Kaufman, R. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950017095 · Cited by 91
Cao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Wang, F., Rendahl, K. G., Manning, W. C., Quiroz, D., Coyne, M., & Miller, S. S. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0281 · Cited by 88
Ross, C. J., Bastedo, L. K., Maier, S. A., Sands, M. S., & Chang, P. L. (2000) · Human Gene Therapy · doi:10.1089/104303400750001426 · Cited by 92
Adeno-Associated Virus Vectors for Short Hairpin RNA Expression
Grimm, D., Pandey, K., & Kay, M. A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)92023-x · Cited by 90
Self-citationGe, Y., Powell, S., Van Roey, M., & McArthur, J. G. (2001) · Blood · doi:10.1182/blood.v97.12.3733 · Cited by 86
Recombinant Adeno-Associated Virus As Delivery Vector for Gene Therapy—A Review
Yang, L. (2004) · Stem Cells and Development · doi:10.1089/154732804773099335 · Cited by 88
Gene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 86
Brunetti-Pierri, N., Nichols, T. C., McCorquodale, S., Merricks, E., Palmer, D. J., Beaudet, A. L., & Ng, P. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.811 · Cited by 79
Self-citationMück-Häusl, M., Zhang, W., Müther, N., Rauschhuber, C., Franck, H. W. G., Merricks, E. P., Nichols, T. C., Kay, M. A., & Ehrhardt, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.169 · Cited by 85
Self-citationHagstrom, J. N., Couto, L. B., Scallan, C., Burton, M., McCleland, M. L., Fields, P. A., Arruda, V. R., Herzog, R. W., & High, K. A. (2000) · Blood · doi:10.1182/blood.v95.8.2536 · Cited by 80
Gene therapy for glycogen storage diseases
Kishnani, P. S., Sun, B., & Koeberl, D. D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz133 · Cited by 83
Mattar, C. N., Nathwani, A. C., Waddington, S. N., Dighe, N., Kaeppel, C., Nowrouzi, A., Mcintosh, J., Johana, N. B., Ogden, B., Fisk, N. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.107 · Cited by 74
Meyer, S. F. D., Vandeputte, N., Pareyn, I., Petrus, I., Lenting, P. J., Chuah, M., VandenDriessche, T., Deckmyn, H., & Vanhoorelbeke, K. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.168369 · Cited by 80
Adeno-Associated Virus-Based Vectors in Gene Therapy
Tal, J. (2000) · Journal of Biomedical Science · doi:10.1007/bf02253246 · Cited by 79
Nathwani, A. C., Hanawa, H., Vandergriff, J. A., Kelly, P., Vanin, E. F., & Nienhuis, A. W. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301068 · Cited by 79
Themis, M., Schneider, H., Kiserud, T., Cook, H. T., Adebakin, S., Jezzard, S., Forbes, S. J., Hanson, M. A., Pavirani, A., Rodeck, C. H., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300970 · Cited by 78
Ehrhardt, A., Xu, H., Huang, Z., Engler, J. A., & Kay, M. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.010 · Cited by 73
Self-citationNichols, T. C., Dillow, A. M., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Arruda, V. R., & High, K. A. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.144 · Cited by 73
Self-citationAdeno-associated virus-mediated gene transfer to hair cells and support cells of the murine cochlea
Stone, I. M., Lurie, D. I., Kelley, M. W., & Poulsen, D. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.005 · Cited by 77
Ehrhardt, A., Xu, H., Dillow, A. M., Bellinger, D. A., Nichols, T. C., & Kay, M. A. (2003) · Blood · doi:10.1182/blood-2003-01-0314 · Cited by 77
Self-citationAllen, J. M., Halbert, C. L., & Miller, A. D. (2000) · Molecular Therapy · doi:10.1006/mthe.1999.0010 · Cited by 73
Cardiac gene therapy with SERCA2a: From bench to bedside
Gwathmey, J. K., Yerevanian, A. I., & Hajjar, R. J. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.11.011 · Cited by 74
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
RetractedGene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Mays, L. E., Wang, L., Lin, J., Bell, P., Crawford, A., Wherry, E. J., & Wilson, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2013.134 · Cited by 62
Farson, D., Harding, T. C., Tao, L., Liu, J., Powell, S., Vimal, V., Yendluri, S., Koprivnikar, K., Ho, K., Twitty, C., et al. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.622 · Cited by 66
Self-citationGene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
Lebherz, C., Sanmiguel, J. C., Wilson, J. M., & Rader, D. J. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-15 · Cited by 73
Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
Peyvandi, F., & Garagiola, I. (2019) · Haemophilia · doi:10.1111/hae.13816 · Cited by 72
Gene Therapy Using Hematopoietic Stem Cells: Sisyphus Approaches the Crest
Halene, S., & Kohn, D. B. (2000) · Human Gene Therapy · doi:10.1089/10430340050032366 · Cited by 72
McIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70
Optimized Production of High-Titer Recombinant Adeno-Associated Virus in Roller Bottles
Liu, Y.-L., Wagner, K., Robinson, N., Sabatino, D., Margaritis, P., Xiao, W., & Herzog, R. W. (2003) · BioTechniques · doi:10.2144/03341dd07 · Cited by 67
Chuah, M., Collen, D., & VandenDriessche, T. (2001) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200101/02)3:1<3::aid-jgm167>3.0.co;2-h · Cited by 70
Ye, P., Thompson, A. R., Sarkar, R., Shen, Z., Lillicrap, D. P., Kaufman, R. J., Ochs, H. D., Rawlings, D. J., & Miao, C. H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.009 · Cited by 70
Self-citationChen, S. J., Rader, D. J., Tazelaar, J., Kawashiri, M., Gao, G., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0122 · Cited by 68
Safety of adeno-associated virus gene therapy vectors: a current evaluation
Monahan, P. E., Jooss, K., & Sands, M. S. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.79 · Cited by 62
Gene therapy for the fetus: is there a future?
David, A. L., & Peebles, D. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.08.008 · Cited by 66
Improvements in adenoviral vector technology: overcoming barriers for gene therapy
Parks, R. J. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.580101.x · Cited by 66
Production of clinical-grade recombinant adeno-associated virus vectors
Snyder, R. O., & Flotte, T. R. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00369-5 · Cited by 65
Self-citationSuppression of Nonsense Mutations in Cell Culture and Mice by Multimerized Suppressor tRNA Genes
Buvoli, M., Buvoli, A. E., & Leinwand, L. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3116-3124.2000 · Cited by 65
Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin
Fakharzadeh, S. S., Zhang, Y., Sarkar, R., & Kazazian, H. H. (2000) · Blood · doi:10.1182/blood.v95.9.2799.009k23_2799_2805 · Cited by 65
Tam, L. C. S., Kiang, A., Kennan, A., Kenna, P. F., Chadderton, N., Ader, M., Palfi, A., Aherne, A., Ayuso, C., Campbell, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn107 · Cited by 64
Schneider, H., Mühle, C., Douar, A. M., Waddington, S. N., Jiang, Q., von der Mark, K., Coutelle, C., & Rascher, W. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.233 · Cited by 64
Gene therapy for the hemophilias
VandenDriessche, T., Collen, D., & Chuah, M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00265.x · Cited by 64
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa
Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M., & Tsang, S. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds466 · Cited by 55
Recent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 60
Immune Responses to AAV Capsid: Are Mice Not Humans After All?
Herzog, R. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300123 · Cited by 56
Optimised helper virus-free production of high-quality adeno-associated virus vectors
Drittanti, L., Jenny, C., Poulard, K., Samba, A., Manceau, P., Soria, N., Vincent, N., Danos, O., & Vega, M. (2001) · The Journal of Gene Medicine · doi:10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u · Cited by 56
Chuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
Somanathan, S., Breous, E., Bell, P., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.40 · Cited by 54
Binny, C., McIntosh, J., Della Peruta, M., Kymalainen, H., Tuddenham, E. G. D., Buckley, S. M. K., Waddington, S. N., McVey, J. H., Spence, Y., Morton, C. L., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377630 · Cited by 54
Gene Transfer as an Approach to Treating Hemophilia
High, K. A. (2001) · Circulation Research · doi:10.1161/01.res.88.2.137 · Cited by 59
Beaty, R. M., Jackson, M., Peterson, D., Bird, A., Brown, T. T., Benjamin, D. K., Juopperi, T. A., Kishnani, P. S., Boney, A., Chen, Y.-T., et al. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301728 · Cited by 57
Sarkar, R., Xiao, W., & Kazazian, H. H. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00096.x · Cited by 57
Harding, T., Koprivnikar, K., Tu, G., Zayek, N., Lew, S., Subramanian, A., Sivakumaran, A., Frey, D., Ho, K. I., VanRoey, M., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302142 · Cited by 57
Self-citationAuricchio, A., Zhou, R., Wilson, J. M., & Glickson, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081508598 · Cited by 56
Oh, H.-J., Park, E. S., Kang, S., Jo, I., & Jung, S. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000132837.29067.0e · Cited by 56
Hortelano, G., Xu, N., Vandenberg, A. L., Solera, J., Chang, P. L., & Ofosu, F. A. (1999) · Human Gene Therapy · doi:10.1089/10430349950017969 · Cited by 55
Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
Creation of a mouse expressing defective human factor IX
Jin, D., Zhang, T.-P., Gui, T., Stafford, D. W., & Monahan, P. E. (2004) · Blood · doi:10.1182/blood-2004-01-0138 · Cited by 54
Self-citationAnand, V., Chirmule, N., Fersh, M., Maguire, A. M., & Bennett, J. (2000) · Human Gene Therapy · doi:10.1089/10430340050015914 · Cited by 54
Balicki, D., & Beutler, E. (2002) · Medicine · doi:10.1097/00005792-200201000-00005 · Cited by 54
Tolerance Induction by Viral In Vivo Gene Transfer
Dobrzynski, E., & Herzog, R. W. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.4.234 · Cited by 47
Role of Hepatocyte Direct Hyperplasia in Lentivirus-Mediated Liver Transduction In Vivo
Ohashi, K., Park, F., & Kay, M. A. (2002) · Human Gene Therapy · doi:10.1089/10430340252837242 · Cited by 52
Self-citationHepatitis B virus infection, its sequelae, and prevention by vaccination
Huang, L.-M., Lu, C.-Y., & Chen, D.-S. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.013 · Cited by 51
Sen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51
Lai, C.-M., Estcourt, M. J., Wikstrom, M., Himbeck, R. P., Barnett, N. L., Brankov, M., Tee, L. B. G., Dunlop, S. A., Degli-Esposti, M. A., & Rakoczy, E. P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3253 · Cited by 44
High, K. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01460.x · Cited by 51
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
Genetic interventions for vein bypass graft disease: A review
Conte, M. S., Mann, M. J., Simosa, H. F., Rhynhart, K. K., & Mulligan, R. C. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.129112 · Cited by 50
Cellular and genetic therapies for haemophilia
LILLICRAP, D., VANDENDRIESSCHE, T., & HIGH, K. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01259.x · Cited by 45
Sollerbrant, K., Elmén, J., Wahlestedt, C., Acker, J., Leblois, H., Latta‐Mahieu, M., Yeh, P., & Perricaudet, M. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-9-2051 · Cited by 50
Zhang, J., Xu, L., Haskins, M. E., & Parker Ponder, K. (2004) · Blood · doi:10.1182/blood-2003-06-2181 · Cited by 50
Gene therapy: principles and applications to hematopoietic cells
Tendeloo, V. F. V., Broeckhoven, C. V., & Berneman, Z. N. (2001) · Leukemia · doi:10.1038/sj.leu.2402085 · Cited by 48
High throughput production, screening and analysis of adeno-associated viral vectors
Drittanti, L., Rivet, C., Manceau, P., Danos, O., & Vega, M. T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301191 · Cited by 48
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
Coagulation Factor IX for Hemophilia B Therapy
Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., & Габибов, А. Г. (2012) · Acta Naturae · doi:10.32607/20758251-2012-4-2-62-73 · Cited by 47
Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13
Zavorotinskaya, T., Tomkinson, A., & Murphy, J. E. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00050-3 · Cited by 47
Animal Models of Hemophilia and Related Bleeding Disorders
Lozier, J. N., & Nichols, T. C. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.03.023 · Cited by 46
Self-citationCongenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia
Hedner, U. K. E., Ginsburg, D., Lusher, J. M., & High, K. A. (2000) · Hematology · doi:10.1182/asheducation-2000.1.241 · Cited by 46
Aubert, D., Ménoret, S., Chiari, E. F., Pichard, V., Durand, S., Tesson, L., Moullier, P., Anegón, I., & Ferry, N. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0561 · Cited by 46
Nichols, T. C., Hough, C. A., Agersø, H., Ezban, M., & Lillicrap, D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13301 · Cited by 45
Self-citationCorrection of factor IX deficiency in mice by embryonic stem cells differentiated in vitro
Fair, J. H., Cairns, B. A., LaPaglia, M., Caballero, M., Pleasant, W. A., Hatada, S., Kim, H., Gui, T., Pevny, L., Meyer, A. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409840102 · Cited by 45
Self-citationArjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Regulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
Soluble Interleukin-13Rα2 Decoy Receptor Inhibits Hodgkin’s Lymphoma Growthin Vitroandin Vivo
Trieu, Y., Wen, X., Skinnider, B., Bray, M. R., Li, Z.-H., Claudio, J. O., Masih‐Khan, E., Zhu, Y.-X., Trudel, S., McCart, J. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3764 · Cited by 44
Schneider, H., Adebakin, S., Themis, M., Cook, H. T., Douar, A. M., Pavirani, A., & Coutelle, C. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199911/12)1:6<424::aid-jgm70>3.0.co;2-q · Cited by 44
Peng, D., Qian, C., Sun, Y., Barajas, M. A., & Prìeto, J. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80102-6 · Cited by 44
Barriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.